-

AmerisourceBergen Elects Redonda Miller, M.D., to its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Redonda Miller, M.D., 56, as a new independent director, effective January 1, 2023.

“We welcome Dr. Miller to the Board of Directors. Her experience as a healthcare leader and as a physician brings great perspective to AmerisourceBergen and our stakeholders,” said Jane E. Henney, M.D., Lead Independent Director.

“Dr. Miller’s healthcare and business experience will help support AmerisourceBergen as we live our purpose of being united in our responsibility to create healthier futures,” said Steven H. Collis, Chairman, President & Chief Executive Officer.

Dr. Miller has served as the president of The Johns Hopkins Hospital since 2016. Previously, she was Chief Medical Officer and Senior Vice President of Medical Affairs for The Johns Hopkins Health System. A practicing internist, Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she was a non-executive director at Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). In 2020, she was inducted into the National Academy of Medicine. In addition, she is a member of the Board of Directors of Gilchrist Hospice Care, Inc. and a member of the Board of Directors of Turnaround Tuesday Inc.

Dr. Miller received her M.D. from The Johns Hopkins University School of Medicine, M.B.A. from The Johns Hopkins University, and B.S. from The Ohio State University.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our more than 43,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at investor.amerisourcebergen.com.

Contacts

Bennett S. Murphy
610-727-3693
Senior Vice President, Investor Relations
bmurphy@amerisourcebergen.com

AmerisourceBergen Corporation

NYSE:ABC

Release Versions

Contacts

Bennett S. Murphy
610-727-3693
Senior Vice President, Investor Relations
bmurphy@amerisourcebergen.com

More News From AmerisourceBergen Corporation

Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm. “We are excited to accelerate our acquisition of OneOncology, which will advance our management services...

Cencora Reports Fiscal 2025 Fourth Quarter and Fiscal Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2025 fourth quarter ended September 30, 2025, revenue increased 5.9 percent to $83.7 billion. Revenue increased 9.3 percent to $321.3 billion for fiscal year 2025. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $(1.75) for the September quarter of fiscal 2025, compared to $0.02 in the prior year quarter. Adjusted diluted EPS, which is a...

Cencora Announces Date and Time for Fourth Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2025 on Wednesday, November 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &...
Back to Newsroom